Agency injects uncertainty into clinic

A dark cloud hovers above the opening of NuMale Medical Center's first Florida-based testosterone replacement therapy center in Tampa — courtesy of the FDA.

The Food and Drug Administration issued a warning last week against testosterone treatments from patients suffering from no more than old age, the primary demographic NuMale serves. But Dr. Christopher Asandra, the founder of NuMale, tells Coffee Talk the FDA is suffering from “premature equivocation.”

“They're basing all of it on two or three flawed studies over the last couple years that don't represent what true testosterone replacement therapy is,” he says. “They're jumping to conclusions before they even get all the facts.”